Methodology
Every provider in our database goes through the same four-step evaluation protocol. We re-evaluate quarterly to keep rankings and pricing current.
Mystery-shopper intake
We complete every provider's intake as a real patient, paying out-of-pocket. No press accounts, no free trials. We use a standardized patient profile (BMI 31, no contraindications, located in a state where the provider operates) so that every provider starts from the same clinical starting point.
We record:
- Time from intake submission to first clinician contact
- Whether a real physician or NP reviewed the chart
- Whether dosage was individually titrated or auto-selected
- Quality and specificity of the clinical consultation
Pharmacy verification
We confirm 503A/503B licensure, request Certificates of Analysis (CoAs), and verify cGMP audit status before listing any compounded medication provider. For brand-name medications, we confirm the provider dispenses through licensed retail or mail-order pharmacies.
Verification checks include:
- State pharmacy board licensure status
- DEA registration (where applicable)
- CoA batch testing for potency and sterility
- Adverse-event reporting history
- Storage and cold-chain compliance documentation
Clinician review
Every clinical claim, dose range, side-effect profile, and drug-interaction warning is sourced from peer-reviewed literature and verified against FDA prescribing information. Our editorial evaluates the provider's clinical protocols, not just marketing copy.
Review scope covers:
- Dosing accuracy and titration recommendations
- Contraindication screening completeness
- Adverse-event monitoring and escalation procedures
- Patient education materials accuracy
- Follow-up care adequacy
Quarterly re-audit
Pricing data revalidates every six hours via automated checks. Full provider reviews are re-conducted every 90 days — repeating steps 1–3 with fresh mystery-shopper accounts to catch changes in clinical protocols, pricing, or pharmacy sourcing.
Re-audit triggers (in addition to quarterly cycle):
- FDA safety communications affecting listed medications
- Provider merger, acquisition, or formulary changes
- Reader-reported pricing discrepancies exceeding 10%
- State-level regulatory changes affecting telehealth GLP-1 prescribing
Scoring Rubric
Each provider receives a composite score (1–10) across five equally-weighted dimensions. Scores are not curved — a provider can score 10/10 if it meets all criteria in a dimension.
Editorial Independence
goglp1.com participates in affiliate programs with several providers listed on this site. We may earn a commission when readers start a program through links labeled "Visit" or "Start intake." However:
- Editorial rankings and scores are produced independently
- Scoring is not adjusted in exchange for commercial relationships
- Affiliate partnerships do not affect a provider's position in our rankings
- Reviewers do not know which providers have affiliate agreements during clinical review
- A provider's affiliate status has no bearing on inclusion or exclusion from our database
For full details, see our disclosures page.
Update Cadence
Trust center
Review how we research, verify, and disclose content decisions across medical, editorial, and legal pages.